The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index.
Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers
Open accessAbstract
Objective: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti–tumor necrosis factor (anti‐TNF) drugs are an important second‐line treatment after methotrexate, the classic first‐line treatment for RA. However, patient heterogeneity hinders identification of predictive biomarkers and accurate modeling of anti‐TNF drug responses. This study was undertaken to investigate the usefulness of machine learning to assist in developing predictive models for treatment response. Methods: Using data on patient demographics, baseline disease assessment, treatment, and single‐nucleotide polymorphism (SNP) array from the Dialogue on Reverse Engineering Assessment and Methods (DREAM): Rheumatoid Arthritis Responder Challenge, we created a Gaussian process regression model to predict changes in the Disease Activity Score in 28 joints (DAS 28) for the patients and to classify them into either the responder or the nonresponder group. This model was developed and cross‐validated using data from 1,892 RA patients. It was evaluated using an independent data set from 680 patients. We examined the effectiveness of the similarity modeling and the contribution of individual features. Results: In the cross‐validation tests, our method predicted changes in DAS 28 (Δ DAS 28), with a correlation coefficient of 0.405. It correctly classified responses from 78% of patients. In the independent test, this method achieved a Pearson's correlation coefficient of 0.393 in predicting Δ DAS 28. Gaussian process regression effectively remapped the feature space and identified subpopulations that do not respond well to anti‐TNF treatments. Genetic SNP biomarkers showed small contributions in the prediction when added to the clinical models. This was the best‐performing model in the DREAM Challenge. Conclusion: The model described here shows promise in guiding treatment decisions in clinical practice, based primarily on clinical profiles with additional genetic information.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite several attempts, including machine learning utilisation,42–44 no single established biomarker has been reported in a real-life setting.45”
From Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study (2024) · cites this paper as [42]
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Gaussian Processes for Machine Learning
Rasmussen, C. E., & Williams, C. K. I. (2005) · doi:10.7551/mitpress/3206.001.0001 · Cited by 11,705
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,742
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., Clair, E. W. S., Fürst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M. H., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 3,059
Intelligible Models for HealthCare: Predicting Pneumonia Risk and Hospital 30-day Readmission
Caruana, R., Lou, Y., Gehrke, J., Koch, P., Sturm, M., & Elhadad, N. (2015) · Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2783258.2788613 · Cited by 1,685
van Gestel, A. M., Prevoo, M. L. L., Hof, M. A. V., van Rijswijk, M. H., van de Putte, L. B. A., & van Riel, P. L. C. M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390105 · Cited by 1,568
Applications of Machine Learning in Cancer Prediction and Prognosis
Cruz, J. A., & Wishart, D. S. (2006) · Cancer Informatics · doi:10.1177/117693510600200030 · Cited by 1,371
FaST linear mixed models for genome-wide association studies
Lippert, C., Listgarten, J., Liu, Y., Kadie, C. M., Davidson, R. I., & Heckerman, D. (2011) · Nature Methods · doi:10.1038/nmeth.1681 · Cited by 1,209
Aletaha, D., Nell, V. P. K., Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K. P., & Smolen, J. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1740 · Cited by 1,064
Research works printed but not linked: 1
- Rose NR, 2013, The autoimmune diseases
Cited by
Sorted by citations
Applied machine learning and artificial intelligence in rheumatology
Hügle, M., Omoumi, P., van Laar, J. M., Boedecker, J., & Hügle, T. (2020) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaa005 · Cited by 187
Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications
Zhao, J., Guo, S., Schrodi, S. J., & He, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790122 · Cited by 167
Peng, J., Jury, E. C., Dönnes, P., & Ciurtin, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720694 · Cited by 162
Momtazmanesh, S., Nowroozi, A. A., & Rezaei, N. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00475-4 · Cited by 149
Adamichou, C., Genitsaridi, I., Nikolopoulos, D., Nikoloudaki, M., Repa, A., Bortoluzzi, A., Fanouriakis, A., Sidiropoulos, P. I., Boumpas, D. T., & Bertsias, G. K. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219069 · Cited by 123
Metadata
- Authors
- Guan, Y., Zhang, H., Quang, D., Wang, Z., Parker, S. C. J., Pappas, D. A., Kremer, J. M., & Zhu, F.
- Affiliations
- University of Michigan (US)
- Columbia University Irving Medical Center (US)
- Center for Rheumatology (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Yuanfang
- ORCID
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2019-11-04
- Volume
- 71
- Issue
- 12
- Pages
- 1987-1996
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2964201896
- Cited by
- 137
- References
- 59
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 18 · 2023: 20 · 2022: 23 · 2021: 36 · 2020: 11 · 2019: 1
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Arthritis & Rheumatology (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- National Natural Science Foundation of China (61802360)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, treatment response prediction, DAS28, Gaussian process regression, single nucleotide polymorphisms, genetic biomarkers, clinical biomarkers, personalized treatment selection
- MeSH terms
- Certolizumab Pegol, Etanercept, Adalimumab, Infliximab, Machine Learning, Arthritis, Rheumatoid, Female, Genetic Markers, Humans, Male, Methotrexate, Middle Aged, Predictive Value of Tests, Regression Analysis, Severity of Illness Index, Tumor Necrosis Factor-alpha, Reproducibility of Results, Normal Distribution, Treatment Outcome, Outcome Assessment, Health Care, Antirheumatic Agents, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
